[HTML][HTML] Increased mortality in community-tested cases of SARS-CoV-2 lineage B. 1.1. 7

NG Davies, CI Jarvis, WJ Edmunds, NP Jewell… - Nature, 2021 - nature.com
NG Davies, CI Jarvis, WJ Edmunds, NP Jewell, K Diaz-Ordaz, RH Keogh
Nature, 2021nature.com
Abstract SARS-CoV-2 lineage B. 1.1. 7, a variant that was first detected in the UK in
September 2020, has spread to multiple countries worldwide. Several studies have
established that B. 1.1. 7 is more transmissible than pre-existing variants, but have not
identified whether it leads to any change in disease severity. Here we analyse a dataset that
links 2,245,263 positive SARS-CoV-2 community tests and 17,452 deaths associated with
COVID-19 in England from 1 November 2020 to 14 February 2021. For 1,146,534 (51%) of …
Abstract
SARS-CoV-2 lineage B.1.1.7, a variant that was first detected in the UK in September 2020, has spread to multiple countries worldwide. Several studies have established that B.1.1.7 is more transmissible than pre-existing variants, but have not identified whether it leads to any change in disease severity. Here we analyse a dataset that links 2,245,263 positive SARS-CoV-2 community tests and 17,452 deaths associated with COVID-19 in England from 1 November 2020 to 14 February 2021. For 1,146,534 (51%) of these tests, the presence or absence of B.1.1.7 can be identified because mutations in this lineage prevent PCR amplification of the spike (S) gene target (known as S gene target failure (SGTF)). On the basis of 4,945 deaths with known SGTF status, we estimate that the hazard of death associated with SGTF is 55% (95% confidence interval, 39–72%) higher than in cases without SGTF after adjustment for age, sex, ethnicity, deprivation, residence in a care home, the local authority of residence and test date. This corresponds to the absolute risk of death for a 55–69-year-old man increasing from 0.6% to 0.9% (95% confidence interval, 0.8–1.0%) within 28 days of a positive test in the community. Correcting for misclassification of SGTF and missingness in SGTF status, we estimate that the hazard of death associated with B.1.1.7 is 61% (42–82%) higher than with pre-existing variants. Our analysis suggests that B.1.1.7 is not only more transmissible than pre-existing SARS-CoV-2 variants, but may also cause more severe illness.
nature.com